Berlin - Delayed Quote EUR

Aelis Farma SA (69O.BE)

Compare
3.3200
+0.9400
+(39.50%)
As of 8:13:03 AM GMT+1. Market Open.
Currency in EUR All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
9,054.0000
9,054.0000
3,809.0000
9,075.0000
--
Operating Expense
15,515.0000
15,515.0000
12,333.0000
6,524.0000
2,839.0000
Operating Income
-6,461.0000
-6,461.0000
-8,524.0000
2,551.0000
-2,839.0000
Net Non Operating Interest Income Expense
260.0000
260.0000
-60.0000
-139.0000
-138.0000
Pretax Income
-5,075.0000
-5,075.0000
-14,287.0000
1,759.0000
-3,042.0000
Tax Provision
3.0000
3.0000
1.0000
1,185.0000
-956.0000
Net Income Common Stockholders
-5,078.0000
-5,078.0000
-14,288.0000
574.0000
-2,086.0000
Diluted NI Available to Com Stockholders
-5,078.0000
-5,078.0000
-14,288.0000
574.0000
-2,086.0000
Basic EPS
-0.39
-0.39
-1.21
0.06
-0.22
Diluted EPS
-0.39
-0.39
-1.21
0.06
-0.22
Basic Average Shares
12,898.7850
12,898.7850
11,839.9910
9,592.7520
9,592.7520
Diluted Average Shares
12,898.7850
12,898.7850
11,839.9910
9,592.7520
9,592.7520
Total Operating Income as Reported
-6,461.0000
-6,461.0000
-8,525.0000
2,552.0000
-2,840.0000
Total Expenses
15,515.0000
15,515.0000
12,333.0000
6,524.0000
2,839.0000
Net Income from Continuing & Discontinued Operation
-5,078.0000
-5,078.0000
-14,288.0000
574.0000
-2,086.0000
Normalized Income
-5,102.0000
-5,102.0000
-10,022.0000
1,588.3000
-2,053.0848
Interest Income
419.0000
419.0000
52.0000
1.0000
1.0000
Interest Expense
159.0000
159.0000
112.0000
140.0000
138.0000
Net Interest Income
260.0000
260.0000
-60.0000
-139.0000
-138.0000
EBIT
-4,916.0000
-4,916.0000
-14,175.0000
1,899.0000
-2,904.0000
EBITDA
-4,580.0000
-4,580.0000
-14,035.0000
1,934.0000
-2,874.0000
Reconciled Depreciation
336.0000
336.0000
140.0000
35.0000
30.0000
Net Income from Continuing Operation Net Minority Interest
-5,078.0000
-5,078.0000
-14,288.0000
574.0000
-2,086.0000
Total Unusual Items Excluding Goodwill
32.0000
32.0000
-5,688.0000
-1,380.0000
-48.0000
Total Unusual Items
32.0000
32.0000
-5,688.0000
-1,380.0000
-48.0000
Normalized EBITDA
-4,612.0000
-4,612.0000
-8,347.0000
3,314.0000
-2,826.0000
Tax Rate for Calcs
0.0003
0.0003
0.0003
0.0003
0.0003
Tax Effect of Unusual Items
8.0000
8.0000
-1,422.0000
-365.7000
-15.0848
12/31/2020 - 2/21/2022

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

SNG.L Synairgen plc
2.5238
+16.04%
 
QLGN Qualigen Therapeutics, Inc.
4.4700
+5.46%
 
GLSI Greenwich LifeSciences, Inc.
13.09
0.00%
 
SLXN Silexion Therapeutics Corp
0.6403
-3.41%
 
REVB Revelation Biosciences, Inc.
0.2510
+2.20%
 
LTRN Lantern Pharma Inc.
4.9750
-7.87%
 
CNSP CNS Pharmaceuticals, Inc.
0.1012
-4.35%
 
ALLR Allarity Therapeutics, Inc.
1.4600
+7.49%
 
CERO CERo Therapeutics Holdings, Inc.
2.2800
-8.06%
 
MBIO Mustang Bio, Inc.
4.3010
-10.21%